# Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

> **NCT00004025** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Genzyme, a Sanofi Company** · enrollment: 36 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** dendritic cell-gp100-MART-1 antigen vaccine

## Key facts

- **NCT ID:** NCT00004025
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1999-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004025, "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00004025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*